FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Drug Safety Monitoring Hurt by FDA Staff Cuts: Post

[ Price : $8.95]

Chemistry & Engineering News reports that reductions in CDER Division of Drug Information staff are affecting FDAs ability to main...

Placebo-controlled Trials Needed for Vaccines: HHS

[ Price : $8.95]

A self-described radical HHS policy now requires all new vaccines to be evaluated in placebo-controlled trials before theyre licen...

FDA Extends Aficamten Review Over REMS Request

[ Price : $8.95]

FDA extends by three months its review of a Cytokinetics NDA for aficamten for treating patients with obstructive hypertrophic car...

Satsuma Migraine Resubmitted NDA Approved

[ Price : $8.95]

FDA approves a Satsuma Pharmaceuticals 505(b)(2) NDA for Atzumi (dihydroergotamine (DHE)) nasal powder for the acute treatment of ...

FDA OKs J&Js Imaavy for Myasthenia Gravis

[ Price : $8.95]

FDA approves a Johnson & Johnson BLA for Imaavy (nipocalimab-aahu) for treating generalized myasthenia gravis.

Unanimous SCOTUS Decision Reassuring: Post

[ Price : $8.95]

George Washington University law professor Richard Pierce praises a recent unanimous Supreme Court decision backing FDA in an e-ci...

Boehringer Drug Shows Encouraging Data in Lung Cancer

[ Price : $8.95]

Boehringer Ingelheim releases new findings from its Beamion LUNG-1 trial, highlighting the potential of zongertinib as a breakthro...

Reopen FDA San Juan Lab: Representatives

[ Price : $8.95]

Reps. Alexandria Orcasio-Cortez and Nydia Velzquez ask HHS secretary Robert F. Kennedy, Jr., to reopen the FDA San Juan medical pr...

Immunic Reports Positive Data on MS Drug

[ Price : $8.95]

Immunic reports positive data from its Phase 2 CALLIPER trial of nuclear receptor related 1 activator vidofludimus calcium (IMU-83...

Gilead Pays $202 Million Over Kickbacks Scheme

[ Price : $8.95]

Gilead Sciences agrees to pay $202 million to resolve claims that the company offered and paid kickbacks (e.g., honoraria payments...